AUTH/3699/10/22 - AstraZeneca v GSK

Allegations about GlaxoSmithKline’s use of a Network Meta-analysis (NMA)  

  • Received
    18 October 2022
  • Case number
  • Applicable Code year
  • Completed
    18 December 2023
  • No breach Clause(s)
  • Breach Clause(s)
  • Sanctions applied
    Undertaking received
  • Additional sanctions
  • Appeal
    No appeal

Case Summary

This case was in relation to GSK’s presentation of a Network Meta-analysis (NMA) on the efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) versus other triple therapies for the treatment of Chronic Obstructive Pulmonary Disease (COPD).

The allegations related to the methodology used to produce the NMA and comparative claims for GSK’s medicine Trelegy (FF/UMEC/VI) versus single-inhaler triple therapies (SITTs), including Trixeo. In addition, AstraZeneca alleged that GSK was in breach of an undertaking provided in relation to a previous case.

The outcome under the 2021 Code was:

Breach of Clause 5.1

Failing to maintain high standards

Breach of Clause 6.1

Making a misleading claim

Breach of Clause 14.1

Making a misleading comparison

No Breach of Clause 2

Requirement that activities or materials must not bring discredit upon, or reduce confidence in, the pharmaceutical industry

No Breach of Clause 3.3

Requirement to comply with an undertaking

No Breach of Clause 6.1

Requirement that comparisons must not be misleading

No Breach of Clause 6.6

Requirement that another company’s medicines must not be disparaged

This summary is not intended to be read in isolation.
For full details, please see the full case report below.